AU2007292295B2 - Fusion peptide therapeutic compositions - Google Patents

Fusion peptide therapeutic compositions Download PDF

Info

Publication number
AU2007292295B2
AU2007292295B2 AU2007292295A AU2007292295A AU2007292295B2 AU 2007292295 B2 AU2007292295 B2 AU 2007292295B2 AU 2007292295 A AU2007292295 A AU 2007292295A AU 2007292295 A AU2007292295 A AU 2007292295A AU 2007292295 B2 AU2007292295 B2 AU 2007292295B2
Authority
AU
Australia
Prior art keywords
elp
protein
thioredoxin
elpi
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007292295A
Other languages
English (en)
Other versions
AU2007292295A1 (en
Inventor
Ashutosh Chilkoti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunoforge Co Ltd
Original Assignee
Immunoforge Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunoforge Co Ltd filed Critical Immunoforge Co Ltd
Publication of AU2007292295A1 publication Critical patent/AU2007292295A1/en
Assigned to PHASEBIO PHARMACEUTICALS, INC. reassignment PHASEBIO PHARMACEUTICALS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: PHASE BIOSCIENCE, INC.
Application granted granted Critical
Publication of AU2007292295B2 publication Critical patent/AU2007292295B2/en
Priority to AU2013224720A priority Critical patent/AU2013224720B2/en
Assigned to Immunoforge Co., Ltd. reassignment Immunoforge Co., Ltd. Request for Assignment Assignors: PHASEBIO PHARMACEUTICALS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2007292295A 2006-09-06 2007-09-06 Fusion peptide therapeutic compositions Active AU2007292295B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013224720A AU2013224720B2 (en) 2006-09-06 2013-09-06 Fusion peptide therapeutic compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84246406P 2006-09-06 2006-09-06
US60/842,464 2006-09-06
PCT/US2007/077767 WO2008030968A2 (en) 2006-09-06 2007-09-06 Fusion peptide therapeutic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013224720A Division AU2013224720B2 (en) 2006-09-06 2013-09-06 Fusion peptide therapeutic compositions

Publications (2)

Publication Number Publication Date
AU2007292295A1 AU2007292295A1 (en) 2008-03-13
AU2007292295B2 true AU2007292295B2 (en) 2013-06-06

Family

ID=39158053

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007292295A Active AU2007292295B2 (en) 2006-09-06 2007-09-06 Fusion peptide therapeutic compositions

Country Status (9)

Country Link
US (3) US20110039776A1 (enExample)
EP (1) EP2059606A4 (enExample)
JP (3) JP5395664B2 (enExample)
CN (2) CN101578373A (enExample)
AU (1) AU2007292295B2 (enExample)
CA (1) CA2663047A1 (enExample)
IL (2) IL197442A (enExample)
MX (1) MX2009002547A (enExample)
WO (1) WO2008030968A2 (enExample)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016271A2 (en) * 2005-07-28 2007-02-08 Global Research Technologies, Llc Removal of carbon dioxide from air
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US7709227B2 (en) * 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
US9359635B2 (en) 2006-04-03 2016-06-07 Promega Corporation Permuted and nonpermuted luciferase biosensors
ATE542903T1 (de) 2008-05-19 2012-02-15 Promega Corp Luciferase-biosensoren für camp
CN105727261A (zh) * 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
US20110229877A1 (en) 2008-07-07 2011-09-22 Oxford Nanopore Technologies Limited Enzyme-pore constructs
CA2730068A1 (en) 2008-07-07 2010-01-14 Oxford Nanopore Technologies Limited Base-detecting pore
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
CN101418290A (zh) * 2008-12-02 2009-04-29 中山大学 一种高效的elp融合蛋白酶及其制备和应用
US8214916B2 (en) 2009-01-26 2012-07-03 Nanoink, Inc. Large area, homogeneous array fabrication including leveling with use of bright spots
EP2391732B1 (en) 2009-01-30 2015-05-27 Oxford Nanopore Technologies Limited Methods using adaptors for nucleic acid constructs in transmembrane sequencing
CN102482330A (zh) * 2009-01-30 2012-05-30 牛津纳米孔技术有限公司 酶突变体
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
US20100316623A1 (en) * 2009-04-23 2010-12-16 Andrew Turner Phenylalanine hydroxylase fusion protein and methods for treating phenylketonuria
IN2012DN02120A (enExample) 2009-08-14 2015-08-21 Phasebio Pharmaceuticals Inc
US8940868B2 (en) * 2009-10-08 2015-01-27 The General Hospital Corporation Elastin based growth factor delivery platform for wound healing and regeneration
WO2011112549A2 (en) * 2010-03-10 2011-09-15 Emory University Temperature sensitive conjugate compositions, and uses related thereto
EP2990479B1 (en) 2010-05-11 2019-03-27 Promega Corporation Mutant protease biosensors with enhanced detection characteristics
US9290794B2 (en) 2010-05-11 2016-03-22 Promega Corporation Mutant protease biosensors with enhanced detection characteristics
CN101955960B (zh) * 2010-08-03 2012-05-23 中山大学 一种利用类弹性蛋白标签纯化重组乳糖酶的方法
BR112013020411B1 (pt) 2011-02-11 2021-09-08 Oxford Nanopore Technologies Limited Monômero de msp mutante, construto, polinucleotídeo, poro, kit e aparelho para caracterizar uma sequência de ácido nucleico alvo, e, método para caracterizar uma sequência de ácido nucleico alvo
US20140088019A1 (en) 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
CN102241747A (zh) * 2011-06-17 2011-11-16 李立文 类人弹性蛋白及其生产方法
KR20140050067A (ko) 2011-07-25 2014-04-28 옥스포드 나노포어 테크놀로지즈 리미티드 막횡단 포어를 사용한 이중 가닥 폴리뉴클레오티드 서열분석을 위한 헤어핀 루프 방법
US9102763B2 (en) 2011-07-26 2015-08-11 University Of Southern California Controlled release of ocular biopharmaceuticals using bioresponsive protein polymers
US20130084277A1 (en) * 2011-08-24 2013-04-04 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
EP2817025A2 (en) * 2012-02-08 2014-12-31 Seneb Biosciences, Inc. Treatment of hypoglycemia
US20130210747A1 (en) 2012-02-13 2013-08-15 University Of Southern California Methods and Therapeutics Comprising Ligand-Targeted ELPs
JP6157877B2 (ja) * 2012-02-28 2017-07-05 三洋化成工業株式会社 組織再生用ゲル、組織再生用タンパク質溶液及び組織再生用ゲルの製造方法
WO2013153359A1 (en) 2012-04-10 2013-10-17 Oxford Nanopore Technologies Limited Mutant lysenin pores
US11155860B2 (en) 2012-07-19 2021-10-26 Oxford Nanopore Technologies Ltd. SSB method
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP2945643A4 (en) * 2013-01-15 2017-04-26 Phasebio Pharmaceuticals, Inc. Therapeutic agents, compositions, and methods for glycemic control
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
CA2901545C (en) 2013-03-08 2019-10-08 Oxford Nanopore Technologies Limited Use of spacer elements in a nucleic acid to control movement of a helicase
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
US10081667B2 (en) 2013-10-01 2018-09-25 University Of Mississippi Medical Center Composition and method for therapeutic agent delivery during pregnancy
US11268127B2 (en) 2014-02-04 2022-03-08 Duke University Systems and devices for protease detection based on engineered polymers and biopolymers and methods of use
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
WO2015164217A1 (en) 2014-04-21 2015-10-29 Theraly Pharmaceuticals Inc. Trail receptor agonists for treatment of fibrotic diseases
US10443097B2 (en) 2014-05-02 2019-10-15 Oxford Nanopore Technologies Ltd. Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
CN119899249A (zh) 2014-09-01 2025-04-29 弗拉芒区生物技术研究所 突变csgg孔
US10266885B2 (en) 2014-10-07 2019-04-23 Oxford Nanopore Technologies Ltd. Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
EP3220936A4 (en) * 2014-11-21 2018-08-22 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
EP3229845B1 (en) 2014-12-10 2020-05-27 University of Southern California Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
ES2822598T3 (es) 2015-02-09 2021-05-04 Phasebio Pharmaceuticals Inc Métodos y composiciones para tratar enfermedades y trastornos musculares
US10639371B2 (en) * 2015-07-29 2020-05-05 University Of Delaware Thermoresponsive bioconjugates and their controlled delivery of cargo
CN106632682A (zh) * 2015-08-04 2017-05-10 清华大学 融合蛋白ifn-elp及其应用
US11458205B2 (en) 2015-08-04 2022-10-04 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
KR101759122B1 (ko) 2015-08-07 2017-07-18 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
US11059870B2 (en) 2016-03-14 2021-07-13 Industry-University Cooperation Foundation Hanyang University Erica Campus Polypeptides with phase transition, triblock polypeptides of the polypeptide-calmodulin-polypeptide with multi-stimuli responsiveness, hydrogel of the triblock polypeptides, and its uses
KR102028931B1 (ko) * 2016-03-24 2019-10-08 한양대학교 에리카산학협력단 지능형 약물 전달을 위한 다중 자극 반응성을 지닌 칼모듈린-엘라스틴 이중 블럭 폴리펩타이드의 동적 나노 전달체 및 제조방법
CN109195620B (zh) 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
KR102646323B1 (ko) * 2016-05-06 2024-03-13 이뮤노포지 주식회사 제어된 지속 방출을 위한 elp 융합 단백질
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
CN107459580A (zh) * 2016-06-06 2017-12-12 易金阳 一种利用酵母菌表达含有穿膜肽的寡肽‑1（egf）创新制备工艺
EP3512868A4 (en) 2016-09-14 2020-04-15 Duke University NANOPARTICLES BASED ON TRIBLOCK POLYPEPTIDE FOR THE DELIVERY OF HYDROPHILIC DRUGS
KR20190064600A (ko) 2016-09-23 2019-06-10 듀크 유니버시티 Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
CN106519040B (zh) * 2016-11-02 2020-03-27 南京大学 一种含肿瘤坏死因子相关凋亡诱导配体的融合蛋白和其制备方法及由该蛋白自组装的纳米粒
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
KR101955366B1 (ko) * 2017-06-02 2019-03-07 인제대학교 산학협력단 인터페론 베타-엘라스틴 재조합 단백질 및 이의 생산방법
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS
JP7074995B2 (ja) * 2017-10-13 2022-05-25 林兼産業株式会社 線維芽細胞増殖促進剤及び線維芽細胞におけるエラスチン産生促進剤
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
CN108531492A (zh) * 2018-04-23 2018-09-14 内蒙古农业大学 利用类弹性蛋白elp构建活性绵羊β-防御素sbd-1体外表达的方法
WO2019213150A1 (en) 2018-04-30 2019-11-07 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
US12269847B2 (en) 2018-08-16 2025-04-08 Donaldson Company, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
WO2020051541A1 (en) 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
WO2021030196A1 (en) * 2019-08-09 2021-02-18 Phasebio Pharmaceuticals, Inc. Elp fusion proteins comprising parathyroid hormone for controlled and sustained release
EP4107167A4 (en) * 2020-02-19 2024-04-03 Donaldson Company, Inc. PROTEIN-BASED PURIFICATION MATRIX AND METHODS OF USE
US12692483B2 (en) 2020-02-19 2026-07-28 Donaldson Company, Inc. Protein-based purification matrices and methods of using the same
EP4107268A4 (en) 2020-02-19 2024-03-27 Donaldson Company, Inc. PURIFICATION MATRICES COMPRISING VAA-BINDING POLYPEPTIDES AND METHODS OF USE THEREOF
WO2021202546A1 (en) 2020-03-31 2021-10-07 Cyclerion Therapeutics, Inc. Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
KR102687389B1 (ko) * 2020-08-25 2024-07-25 한양대학교 에리카산학협력단 자극 반응성 및 표면 부착성을 가진 점착성 엘라스틴 및 서커린 기반 다중 블록 코폴리펩타이드, 그의 자가조립 구조체 및 주사형 하이드로겔의 생접착제 응용
KR20230125179A (ko) 2020-12-23 2023-08-29 재즈 파마슈티칼즈 아일랜드 리미티드 전하-차폐 융합 단백질의 정제 방법
CN117279936A (zh) * 2021-02-19 2023-12-22 唐纳森公司 包含具有相行为的蛋白的融合蛋白
US20250368708A1 (en) * 2022-05-23 2025-12-04 Fudan University TREFOIL FACTOR 2/INTERFERON alpha2 FUSION PROTEIN AND APPLICATION THEREOF IN PREVENTION AND TREATMENT OF VIRAL INFECTIOUS DISEASES
CN115724915B (zh) * 2022-08-17 2025-08-12 上普博源（北京）生物科技有限公司 类弹性蛋白多肽粘合剂及其制备方法与应用
CN117777303A (zh) * 2022-09-27 2024-03-29 北京大学 一种高亲和力pd1蛋白偶联物及其应用
JP2025541413A (ja) * 2022-12-27 2025-12-18 ネクスセラ カンパニー リミテッド エラスチン類似ポリペプチド基盤の組換えタンパク質の作製及びその動物細胞発現プラットフォーム
CN116617409A (zh) * 2023-04-06 2023-08-22 北京大学 一种降低免疫原和增强抗肿瘤功效的asp-elp及其制备方法与应用
WO2025076213A1 (en) * 2023-10-04 2025-04-10 The Board Of Trustees Of The Leland Stanford Junior University Isothermally phase-separable elastin-like polypeptides, compositions, and methods of use thereof
JPWO2025100511A1 (enExample) * 2023-11-10 2025-05-15
WO2026005476A1 (ko) * 2024-06-26 2026-01-02 주식회사 넥스세라 혈소판 감소증 치료를 위한 재조합 단백질 및 이의 용도
WO2026158523A1 (en) * 2025-01-24 2026-07-30 Tj Biopharma (Hangzhou) Co., Ltd. Masked multifunctional proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375393T1 (de) * 1998-01-30 2007-10-15 Asubio Pharma Co Ltd Verfahren zur herstellung eines peptids mittels eines hilfspeptids
US6852834B2 (en) * 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US20050255554A1 (en) * 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
US20030098869A1 (en) * 2001-11-09 2003-05-29 Arnold Glenn Christopher Real time interactive video system
CN102268094A (zh) * 2002-08-30 2011-12-07 比奥雷克西斯药物公司 被修饰的转铁蛋白抗体的融合蛋白
ES2371072T3 (es) * 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
JP4149867B2 (ja) * 2003-07-28 2008-09-17 キヤノンファインテック株式会社 プリンタ、その制御方法
US7019845B1 (en) * 2004-10-06 2006-03-28 Rudolph Technologies, Inc. Measuring elastic moduli of dielectric thin films using an optical metrology system
WO2006110292A2 (en) * 2005-03-25 2006-10-19 The Regents Of The University Of California Temperature-triggered immobilization and purification of antibodies

Also Published As

Publication number Publication date
US20130143802A1 (en) 2013-06-06
US20110039776A1 (en) 2011-02-17
JP2016026167A (ja) 2016-02-12
JP5395664B2 (ja) 2014-01-22
EP2059606A4 (en) 2010-04-07
JP2010502734A (ja) 2010-01-28
MX2009002547A (es) 2009-06-19
IL197442A (en) 2015-04-30
WO2008030968A3 (en) 2008-11-13
CN103230598A (zh) 2013-08-07
JP5802250B2 (ja) 2015-10-28
CA2663047A1 (en) 2008-03-13
US20130178416A1 (en) 2013-07-11
WO2008030968A2 (en) 2008-03-13
CN101578373A (zh) 2009-11-11
IL197442A0 (en) 2011-08-01
AU2007292295A1 (en) 2008-03-13
EP2059606A2 (en) 2009-05-20
JP2014051510A (ja) 2014-03-20
IL232825A0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
US20110039776A1 (en) Fusion peptide therapeutic compositions
US6852834B2 (en) Fusion peptides isolatable by phase transition
US20090220455A1 (en) Pharmaceutical compositions comprising elp fusion proteins
CN102131516B (zh) 包含弹性蛋白样肽的治疗剂
KR101993714B1 (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
AU2019218786B2 (en) Cell-permeable stapled peptide modules for cellular delivery
AU2009307249B2 (en) Bipodal peptide binder
CN102164949B (zh) 新型重组融合蛋白
WO2014165093A2 (en) Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
EP3060235B1 (en) Endoglin peptides to treat fibrotic diseases
CN103641896B (zh) 明胶样单元的用途
WO2011071280A2 (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
JP2022511280A (ja) 免疫調節特性を有するペプチド
AU2013224720B2 (en) Fusion peptide therapeutic compositions
Huang et al. Fused hydrophobic elastin-like-peptides (ELP) enhance biological activity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
KR102897184B1 (ko) 반감기 연장 약물 및 이의 라이브러리, 및 이의 제조 방법과 응용
US8586544B2 (en) Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component
Xu et al. Fusion of parathyroid hormone (1–34) to an albumin-binding domain improves osteogenesis
RU2753191C2 (ru) Новый рекомбинантный аналог гормона роста пролонгированного действия
CN115960246A (zh) 一种重组环状人生长激素-Fc融合蛋白及其应用
HK1228288B (en) Endoglin peptides to treat fibrotic diseases
HK1228288A1 (en) Endoglin peptides to treat fibrotic diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: IMMUNOFORGE CO., LTD.

Free format text: FORMER OWNER(S): PHASEBIO PHARMACEUTICALS, INC.